7. April 2016: Julian Hitchcock spoke at the Royal Society of Medicine

Julian spoke at the Royal Society of Medicine on the impact of the General Data Protection Regulation and other impending EU regulations on medical and healthcare apps and related digital healthcare systems.

8. February 2016: Julian Hitchcock wrote an article for BioNews entitled ‘The distracting genome’

In an article published in BioNews (here), Julian discusses the regulation of embryonic gene editing in the UK following the HFEA's decision to extend the Francis Crick Institute's research licence to include studies involving CRISPR/Cas9 embryonic gene editing.

4. February 2016: Julian Hitchcock spoke at Informa’s Genome Editing Applications Conference

Julian spoke on regulatory strategies for translating genome editing and CRISPR therapeutics into the clinic at Informa's Genome Editing Applications Conference in Brussels.

26. January 2016: Julian Hitchcock spoke at the University of Cambridge’s inter-disciplinary workshop

Julian spoke at the University of Cambridge's inter-disciplinary workshop on gene editing at Jesus College, Cambridge. The meeting was organised by the University's Public Policy Strategic Initiative in association with the Welcome Trust - Medical Research Council Cambridge Stem Cell Institute.

20. January 2016: Julian Hitchcock spoke at the Festival of Genomics in London

Julian spoke on human embryonic gene editing in research at the Festival of Genomics in London. The discussion was organised by the Progress Educational Trust.

12. January 2016: Launch of the textbook 'Stem Cells in Regenerative Medicine'

Denoon Legal congratulates Alain Vertes, Nasib Quershi, Arnold Caplan and Lee Babiss on the launch of the comprehensive textbook 'Stem Cells in Regenerative Medicine' published by Wiley Blakewell (here).

Alex Denoon and Julian Hitchcock of Denoon Legal were proud to contribute a chapter regarding the European regulatory and IP landscape together with James Lawford Davies.

15. September 2015: Julian Hitchcock appointed as a Trustee at Science Media Centre (“SMC”)

We are very pleased to announce that Julian has been appointed as a Trustee at the Science Media Centre (“SMC”). The SMC is an independent venture working to promote the voices, stories and views of the scientific community to the national news media when science is in the headlines. 

14. September 2015: Alex Denoon attended a meeting organised by the European Alliance for Personalised Medicine

Alex attended a meeting in Brussels organised by the European Alliance for Personalised Medicine. This was the "kick off" meeting of the Health Data Access & Accountability Task Force. Attendees included representatives from patient organisations, clinicians and researchers; pharmaceutical companies; software and hardware companies and representatives from European Commission.

9. September 2015: Alex Denoon participated in the ABPI Legal Day at the RSM on 9 September 2015

Alex co-presented on managing a disaster scenario with Dominic Hornblow from Astra Zeneca and Aileen Thompson from the ABPI.

7. September 2015: Julian Hitchcock spoke on the impact of regulation on innovation policy at @MEIbioeng15

On 7 September, Julian spoke on the impact of regulation on innovation policy at @MEIbioeng15, the UK’s largest gathering of biomedical engineers, bioengineers and medical engineers. The event was organised by the Royal Academy of Engineering and the University of Leeds.

10. July 2015: Julian Hitchcock is giving a series of one-to-one life science clinics at the Judge Business School of the University of Cambridge

Julian helped to found the life science stream of the University's international enterprise course, Ignite, in 2010. Details may be found here.

1. July 2015: We're pleased to announce the launch of Denoon Legal, the exclusive life sciences law firm.

We will continue to focus solely on Life Sciences, working with our colleagues and friends in the Alliance of European Life Sciences Law Firms, to continue to deliver specialist advice to life sciences leaders in this dynamic sector. Clients demand specialist advice to manage the fast-moving legal, regulatory and policy landscape in Europe and the UK.

James Lawford Davies has joined Hempsons, a leading UK healthcare practice. We wish James well in his new role.

Denoon Legal Limited is the same legal entity as Lawford Davies Denoon Limited and maintains the same registration details and service offering.

10. February 2015: Alex Denoon presented at the Clinical Operations & Outsourcing Medical Device Trials Conference in Munich on 10 – 11 February 2015

Alex spoke at the Clinical Operations & Outsourcing Medical Device Trials Conference in Munich on 11 February 2015. Alex gave a presentation on the ‘Ramifications of the changes to data protection framework on clinical investigations’.

29. January 2015: Alex Denoon presented at the IMCAS Annual World Congress 2015 Conference in Paris

Alex spoke at the IMCAS Annual World Congress 2015 Conference in Paris on 29 January 2015. Alex gave a presentation on the ‘Regulation of Stem Cell Therapies in UK’.

18. December 2014: LDD was cited in Nature’s report of the decision by the Court of Justice of the European Union in International Stem Cell Corporation v Comptroller General of Patents, Designs and Trade Marks

Today, the Court of Justice of the European Union (“CJEU”) gave its judgment in the important stem cell patent case, International Stem Cell Corporation v Comptroller General of Patents, Designs and Trade Marks. Nature’s report of the decision, which concerned the patentability of human parthenotes in Europe, reported remarks by LDD’s Julian Hitchcock about serious evidential flaws in the landmark Brüstle case of 2011. 

21. November 2014: Julian Hitchcock will be giving a lecture at Hughes Hall, University of Cambridge on 28 November 2014

Julian is giving a lecture on "Inflammatory property: the ambiguous relationship between life sciences and intellectual property" at Hughes Hall, University of Cambridge on 28 November 2014.

20. November 2014: Julian Hitchcock spoke at a joint meeting of the Academy of Medical Sciences and the Royal Academy of Engineering

Julian gave a presentation on the law and regulation of health apps at a joint meeting of the Academy of Medical Sciences and the Royal Academy of Engineering in London on 18 November 2014.

6. October 2014: Lawford Davies Denoon recommended by Legal 500 in Pharmaceuticals and Biotechnology


Lawford Davies Denoon is delighted to be recognised as ‘a niche life sciences firm’ with ‘specialist regulatory and litigation capabilities, in areas such as medical devices, cell therapies and IVF law’ in the latest (2014) edition of the Legal 500. Alex Denoon is commended for delivering ‘out-of-the-box solutions'. Julian Hitchcock recognised as ‘commercially astute with technical insight’. Please see here for the full review.

23. July 2014: Julian Hitchcock was guest blogger for this week's Managing Intellectual Property


Julian Hitchcock, as guest blogger for this week's Managing Intellectual Property, writes on the potential impact of the International Stem Cell patent case in the Court of Justice of the European Union (here).

22. July 2014: UK Government's Review of the Competences between the United Kingdom and the European Union: Fundamental Rights


Evidence from Lawford Davies Denoon, in connection with the life science sector, figured in the UK Government's Review of the Competences between the United Kingdom and the European Union: Fundamental Rights, published on 22 July 2014 (here).

21. May 2014: Julian Hitchcock spoke at the Entrepreneurship: Emerging Technologies (ETECH Projects) Programme


Julian spoke at the Entrepreneurship: Emerging Technologies (ETECH Projects) Programme, hosted by the Judge Business School, University of Cambridge, on 21 May 2014. Julian presented a lecture on intellectual property exploitation to MPhil and MBA students (Emerging Technologies Projects).

14. April 2014: Wellcome Trust stands up for EU funded research


LDD is supporting the Wellcome Trust, which has lead a group of 31 research organisations across Europe in a statement opposing radical legislative proposals contained in the “One of Us” citizens’ initiative, the effect of which would be to block EU funding for research involving the use of surplus IVF embryos and to threaten implementation of the fifth UN Millenium Development Goal which seeks to ensure universal access to reproductive health. Interviewed by Science magazine, Julian Hitchcock said that the Brüstle patent case, upon which the campaigners rest their case, does not declare the point at which human life and dignity begins.

7. April 2014: European Society of Human Genetics today publishes a legal Opinion by LDD and Axon


European Society of Human Genetics
today publishes a legal Opinion by LDD and Axon, challenging the legitimacy of controversial amendments to the proposed IVD Regulation.

20. March 2014: Alex Denoon co-chaired a session on ‘Intellectual Property: The Legal view’

Alex co-chaired a session on ‘Intellectual Property: The Legal view’at the 17th International Conference on Pharmaceutical Medicine and 30th DGPharMed Annual Meeting in Berlin on 20th March 2014.

13. March 2014: HFEA decide not to appeal against Beth Warren

We are very pleased that the HFEA have decided not to appeal against last week's High Court judgment. The HFEA issued a press release here which states that they "have concluded that the likelihood of future problems is not strong enough to warrant appealing in this case". Beth is now free to use the stored samples in accordance with the Court's declaration and we wish her all the very best for the future.

6. March 2014: Victory for Beth Warren

We are delighted that the High Court today confirmed that Beth's application for a declaration allowing her late husband's sperm to remain in storage has been successful. A copy of the judgment is available here and the judge's summary is here.  

19. February 2014: Alex presented at the Clinical Operations & Outsourcing Medical Device Trials 2014 Conference in Frankfurt on 19 February 2014

Alex Denoon presented at a conference (Clinical Operations & Outsourcing Medical Device Trials 2014) in Frankfurt on 19 February 2014. Alex's lecture related to the changing regulatory framework (for medical devices, in-vitro diagnostics, data protection and clinical trials).

31. January 2014: Alex attended a workshop considering Strategies for Responsible Sharing of Clinical Trial Data

Alex Denoon was invited to attend a workshop hosted by The Wellcome Trust on 31 January 2014 considering Strategies for Responsible Sharing of Clinical Trial Data. The workshop was based on a Study by the US Institute of Medicine. The workshop discussed the challenges with establishing systems for sharing clinical data. Based on his practical experience, Alex was able to comment on technical and legal issues (with a focus on the changing regulatory landscape).

4. December 2013: LDD acting for Beth Warren

LDD is acting for Elizabeth Warren in relation to her application to the High Court for a declaration that it would be lawful for her late husband's sperm to remain in storage. Further information is set out in this press release.

3. December 2013: ARGC and RGI v HFEA success

LDD acted for the Assisted Reproduction and Gynaecology Centre and the Reproductive Genetics Institute in their successful judicial review of the Human Fertilisation and Embryology Authority's decision to vary the clinics' licences before the completion of a statutory appeals process. Mrs Justice Patterson said that "In my judgment the defendant has no power to impose a condition which takes effect on a licence prior to completion of the full statutory process up to and including the appeal process provided for in section 20 of the 1990 Act" and further that "...the conduct of the defendant towards the claimants has not been fair. A fair outcome would have been to have retained the status quo until the end of the appeals process". The clinics were awarded their costs and a copy of the full judgment is available here.

21. June 2012: Julian Hitchcock confirmed as a member of the Emerging Science and Bioethics Advisory Committee (ESBAC)

We are very pleased to announce that Julian Hitchcock of Lawford Davies Denoon has been confirmed as a member of the newly established Emerging Science and Bioethics Advisory Committee (ESBAC).

ESBAC is the main UK advisory body on the wider implications of developments in bioscience and its impact for health. The Committee is sponsored by the Chief Scientific Advisor for the Department of Health, England and aims to provide advice to UK Health Departments on emerging healthcare scientific developments and their ethical, legal, social and economic implications. The Committee also provides a forum to consider and develop coordinated advice across the wider science, health and academic communities to help set priorities in response to new developments.

The Committee provides expertise in health related biosciences and biotechnology, medicine as well as social, ethical, legal, commercial and public communication issues. Members hold office for up to three years and are not remunerated.

 

1. April 2012: Alex Denoon will be presenting a Masterclass on the Bribery Act in the Life Sciences Sector on 2 April 2012

Alex Denoon will be presenting a Masterclass on the Bribery Act in the Life Sciences Sector, with country specific commentary from Mathias Klümper re: Germany and Erik Vollebregt re: The Netherlands, at the SMi 'A Practical Guide to Implementing the Bribery Act in the Life Sciences Sector' Conference in London on 2 April 2012.

26. March 2012: Alex attends Commission Workshop on "Stem Cell Research and Patenting" in Brussels on 19 March 2012

Alex attends Commission Workshop on "Stem Cell Research and Patenting" in Brussels on 19 March 2012. 

20. December 2011: Alex Denoon to speak at a meeting at the Wellcome Trust: Embryonic Stem Cell Research: Beyond ‘Brüstle v Greenpeace’ on 21 December 2011

Alex will be giving a presentation on ‘Practical Ramifications of Brüstle v Greenpeace?’ at the Embryonic Stem Cell Research: Beyond ‘Brüstle v Greenpeace’ Meeting on 21 December 2011 at the Wellcome Trust, London.

1. November 2011: Alex Denoon to speak at the Informa Life Sciences’ Cell Therapy Manufacturing Conference in Brussels: 30 November to 1 December 2011

Alex will be giving a presentation on 'How are cell therapies protected under IP and regulatory frameworks?' along with Anton Hutter of Venner Shipley and Dr Christopher Bravery of Consulting on Advanced Biologicals at the Informa Life Sciences’ Cell Therapy Manufacturing Conference in Brussels on 30 November 2011.

21. October 2011: Radio Interview re Brüstle v Greenpeace

Alex Denoon was interviewed by Material World (the leading radio science programme) on BBC Radio on 20 October with a representative from Greenpeace Germany. They discussed the decision of the Court of Justice of the European Union on the patentability of embryonic stem cells. The interview can he found here.

20. September 2011: Alex Denoon appointed as a Trustee at Science Media Centre (“SMC”)

We are very pleased to announce that Alex has been appointed as a Trustee at the Science Media Centre (“SMC”). The SMC is an independent venture working to promote the voices, stories and views of the scientific community to the national news media when science is in the headlines. We are honoured to be asked to assist an organisation with as enviable a reputation as SMC.

24. August 2011: Alex Denoon co-authors editorial ‘The Ramifications of the Advocate General's Opinion in the Oliver Brüstle Case'

Alex Denoon and Mark Paton (from Fasken Martineau LLP) co-authored an editorial entitled ‘The Ramifications of the Advocate General's Opinion in the Oliver Brüstle Case’ which is scheduled to appear in Issue 9 of the EIPR (European Intellectual Property Review). 

24. August 2011: Alex Denoon co-authors editorial ‘Hard Cell'

Alex Denoon and Mark Paton (from Fasken Martineau LLP) co-authored an editorial entitled ‘Hard Cell’ which appeared in the May 2011 edition of the European Lawyer. The editorial addressed whether the recent opinion from the EU's Court of Justice could throw stem cell patents into turmoil.